Edwards Lifesciences Corporation (VIE:EWLS)

Market Cap	41.44B +11.9%
Revenue (ttm)	5.47B +14.1%
Net Income	950.73M -73.8%
EPS	1.63 -73.2%
Shares Out	n/a
PE Ratio	43.59
Forward PE	27.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	0
Open	71.60
Previous Close	70.78
Day's Range	71.28 - 71.60
52-Week Range	61.81 - 75.41
Beta	n/a
RSI	55.45
Earnings Date	Apr 23, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 16,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: EWLS

Financial Performance

In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.

Financial numbers in USD